Bachem Holding AGBCHMF 91 ROE % is 14.14% as of Dec. 2025, which is 24% above its 10-year median of 11.39. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $98.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,255 Biotechnology companies, Bachem Holding AG ranks better than 89% on this metric.
The historical rank and industry rank for Bachem Holding AG's ROE % or its related term are showing as below:
BCHMF'
s ROE % Range Over the Past 10 Years
Min: 8.79 Med: 11.39 Max: 16.91
Current: 10.6
During the past 13 years, Bachem Holding AG's highest ROE % was 16.91%. The lowest was 8.79%. And the median was 11.39%.
BCHMF's ROE % is ranked better than 89% of 1255
companies
in the Biotechnology industry
Industry Median: -38.34
vs BCHMF: 10.60
Bachem Holding AG (OTCPK:BCHMF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Bachem Holding AG ROE % Related Terms
Bachem Holding AG ROE % Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bachem Holding AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's ROE % distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Bachem Holding AG (BCHMF) has a ROE % of 14.14% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bachem Holding AG and its competitors. This is 24% above median its historical median of 11.39. Over the past decade, Bachem Holding AG's ROE % has ranged from 8.79 to 16.91. According to the industry distribution chart, Bachem Holding AG ranks #138 out of 1255 companies in the Biotechnology industry, placing it in the top 11%.
Is Bachem Holding AG's ROE % too high?
Bachem Holding AG's current ROE % of 14.14% is 24% above median its 10-year median of 11.39. Over the past 10 years, this metric has ranged from a low of 8.79 to a high of 16.91. Based on the distribution chart, Bachem Holding AG ranks #138 out of 1255 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #138 out of 1255 companies for ROE %. This places Bachem Holding AG in the top 11% of its industry — outperforming the majority of peers. Historically, Bachem Holding AG's own ROE % has ranged from 8.79 to 16.91 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bachem Holding AG and its competitors. Bachem Holding AG's current ROE % is 14.14%, which is 24% above median its own 10-year median of 11.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.06, compared to a current price of $87.34 — trading 10.9% below its estimated fair value. The current ROE % is 14.14%, which is 24% above median its 10-year median of 11.39. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current ROE % is 14.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 10.9% below its estimated GF Value™ of $98.06.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
ROE %: 14.14% (24% above median its 10-year median of 11.39)
GF Value™: $98.06 vs. price of $87.34 (10.9% below fair value)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
